BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 20972533)

  • 1. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
    Maida A; Lamont BJ; Cao X; Drucker DJ
    Diabetologia; 2011 Feb; 54(2):339-49. PubMed ID: 20972533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.
    Cho YM; Kieffer TJ
    Diabetologia; 2011 Feb; 54(2):219-22. PubMed ID: 21116606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
    Flock G; Holland D; Seino Y; Drucker DJ
    Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
    Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
    J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.
    Ali S; Lamont BJ; Charron MJ; Drucker DJ
    J Clin Invest; 2011 May; 121(5):1917-29. PubMed ID: 21540554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
    Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
    Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
    Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
    Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells.
    Aoyama E; Watari I; Podyma-Inoue KA; Yanagishita M; Ono T
    Int J Mol Med; 2014 Aug; 34(2):475-82. PubMed ID: 24866833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells.
    Shilleh AH; Viloria K; Broichhagen J; Campbell JE; Hodson DJ
    Peptides; 2024 May; 175():171179. PubMed ID: 38360354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
    Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
    Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
    Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
    Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
    Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
    Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reagents and models for detecting endogenous GLP1R and GIPR.
    Ast J; Broichhagen J; Hodson DJ
    EBioMedicine; 2021 Dec; 74():103739. PubMed ID: 34911028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.